{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:23:20Z","timestamp":1790717000887,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BJC Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The implementation of mainstream germline genetic testing in breast cancer patients has both benefits and challenges. Multiple aspects need to be considered for the outline of gene panels and the amount of pre-test genetic counselling. Mainstream genetic testing is mainly performed to stratify patients for targeted treatment. In addition, identification of germline pathogenic variants in cancer risk genes may have surgical implications, consequences for surveillance of other organs at risk of cancer, as well as family implications among relatives at risk. To ensure that patients are well informed, the introduction of mainstream genetic testing performed by non-genetic health care specialists requires an adapted pre-test counselling visit. Here, we review the literature and propose a web-based educational session and pocket guide to support implementation of mainstream testing in oncology practice.<\/jats:p>","DOI":"10.1038\/s44276-025-00202-w","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T13:54:51Z","timestamp":1770126891000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Implementing mainstream germline genetic testing in breast cancer across Europe"],"prefix":"10.1038","volume":"4","author":[{"given":"Eduard","family":"P\u00e9rez-Ballestero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagal Ahmed","family":"Shire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateja","family":"Krajc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arv\u012bds","family":"Irmejs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka","family":"Foretov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiina","family":"Kahre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"van Overeem Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linetta","family":"Koppert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Lena","family":"Burgemeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Tischkowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Balma\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Bajalica-Lagercrantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of ERN GENTURIS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"202_CR1","doi-asserted-by":"crossref","unstructured":"Hynes J, MacMillan A, Fernandez S, Jacob K, Carter S, Predham S, et al. Group plus \"mini\" individual pre-test genetic counselling sessions for hereditary cancer shorten provider time and improve patient satisfaction. Hered Cancer Clin Pract. 2020;18:3.","DOI":"10.1186\/s13053-020-0136-2"},{"key":"202_CR2","doi-asserted-by":"crossref","unstructured":"Hallquist MLG, Tricou EP, Ormond KE, Savatt JM, Coughlin CR, Faucett WA, et al. Application of a framework to guide genetic testing communication across clinical indications. Genome Med. 2021;13.","DOI":"10.1186\/s13073-021-00887-x"},{"key":"202_CR3","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ejca.2018.10.007","volume":"106","author":"CF Singer","year":"2019","unstructured":"Singer CF, Balma\u00f1a J, B\u00fcrki N, Delaloge S, Filieri ME, Gerdes AM, et al. Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer-an European consensus statement and expert recommendations. Eur J Cancer. 2019;106:54\u201360.","journal-title":"Eur J Cancer"},{"key":"202_CR4","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1038\/s41436-021-01262-2","volume":"23","author":"JG Hamilton","year":"2021","unstructured":"Hamilton JG, Symecko H, Spielman K, Breen K, Mueller R, Catchings A, et al. Uptake and acceptability of a mainstreaming model of hereditary cancer multigene panel testing among patients with ovarian, pancreatic, and prostate cancer. Genet Med. 2021;23:2105\u201313.","journal-title":"Genet Med"},{"key":"202_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-60149-5","volume":"10","author":"M Rumford","year":"2020","unstructured":"Rumford M, Lythgoe M, McNeish I, Gabra H, Tookman L, Rahman N, et al. Oncologist-led BRCA 'mainstreaming' in the ovarian cancer clinic: a study of 255 patients and its impact on their management. Sci Rep. 2020;10:3390.","journal-title":"Sci Rep"},{"key":"202_CR6","doi-asserted-by":"publisher","first-page":"e2232787","DOI":"10.1001\/jamanetworkopen.2022.32787","volume":"5","author":"PW Whitworth","year":"2022","unstructured":"Whitworth PW, Beitsch PD, Patel R, Rosen B, Compagnoni G, Baron PL, et al. Clinical utility of universal germline genetic testing for patients with breast cancer. JAMA Netw Open. 2022;5:e2232787.","journal-title":"JAMA Netw Open"},{"key":"202_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/srep29506","volume":"6","author":"A George","year":"2016","unstructured":"George A, Riddell D, Seal S, Talukdar S, Mahamdallie S, Ruark E, et al. Implementing rapid, robust, cost-effective, patient-centered, routine genetic testing in ovarian cancer patients. Sci Rep. 2016;6:29506.","journal-title":"Sci Rep"},{"key":"202_CR8","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41431-022-01080-3","volume":"30","author":"M Paneque","year":"2022","unstructured":"Paneque M, Liehr T, Serra Juh\u00e9 C, Moog U, Melegh B, Carreira I. The need for recognition of core professional groups in genetics healthcare services in Europe. Eur J Hum Genet. 2022;30:639\u201340.","journal-title":"Eur J Hum Genet"},{"key":"202_CR9","doi-asserted-by":"publisher","first-page":"1140135","DOI":"10.3389\/fonc.2023.1140135","volume":"13","author":"R O'Shea","year":"2023","unstructured":"O'Shea R, Crook A, Jacobs C, Kentwell M, Gleeson M, Tucker KM, et al. A mainstreaming oncogenomics model: improving the identification of Lynch syndrome. Front Oncol. 2023;13:1140135.","journal-title":"Front Oncol"},{"key":"202_CR10","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s10689-015-9852-6","volume":"15","author":"KF Douma","year":"2016","unstructured":"Douma KF, Smets EM, Allain DC. Non- genetic health professionals' attitude towards, knowledge of and skills in discussing and ordering genetic testing for hereditary cancer. Fam Cancer. 2016;15:341\u201350.","journal-title":"Fam Cancer"},{"key":"202_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-018-0337-y","volume":"11","author":"VTD Ha","year":"2018","unstructured":"Ha VTD, Frizzo-Barker J, Chow-White P. Adopting clinical genomics: a systematic review of genomic literacy among physicians in cancer care. BMC Med Genom. 2018;11:18.","journal-title":"BMC Med Genom"},{"key":"202_CR12","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.3390\/cancers14041059","volume":"14","author":"K Bokkers","year":"2022","unstructured":"Bokkers K, Vlaming M, Engelhardt EG, Zweemer RP, van Oort IM, Kiemeney, et al. The feasibility of implementing mainstream germline genetic testing in routine cancer care-a systematic review. Cancers. 2022;14:1059.","journal-title":"Cancers"},{"key":"202_CR13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13053-022-00238-w","volume":"20","author":"K Bokkers","year":"2022","unstructured":"Bokkers K, Bleiker EMA, Hoogendam JP, Velthuizen ME, Schreuder HWR, Gerestein CG, et al. Mainstream genetic testing for women with ovarian cancer provides a solid basis for patients to make a well-informed decision about genetic testing. Hereditary Cancer Clin Pract. 2022;20:33.","journal-title":"Hereditary Cancer Clin Pract"},{"key":"202_CR14","doi-asserted-by":"publisher","first-page":"e194428","DOI":"10.1001\/jamanetworkopen.2019.4428","volume":"2","author":"Z Kemp","year":"2019","unstructured":"Kemp Z, Turnbull A, Yost S, Seal S, Mahamdallie S, Poyastro-Pearson E, et al. Evaluation of cancer-based criteria for use in mainstream BRCA1 and BRCA2 genetic testing in patients with breast cancer. JAMA Netw Open. 2019;2:e194428.","journal-title":"JAMA Netw Open"},{"key":"202_CR15","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1200\/JCO.19.00363","volume":"37","author":"SM Domchek","year":"2019","unstructured":"Domchek SM, Robson ME. Update on genetic testing in gynecologic cancer. J Clin Oncol. 2019;37:2501\u20139.","journal-title":"J Clin Oncol"},{"key":"202_CR16","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/cge.12405","volume":"87","author":"ST Vadaparampil","year":"2015","unstructured":"Vadaparampil ST, Scherr CL, Cragun D, Malo TL, Pal T. Pre-test genetic counseling services for hereditary breast and ovarian cancer delivered by non- genetics professionals in the state of Florida. Clin Genet. 2015;87:473\u20137.","journal-title":"Clin Genet"},{"key":"202_CR17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s10549-017-4643-4","volume":"169","author":"HJ Pederson","year":"2018","unstructured":"Pederson HJ, Hussain N, Noss R, Yanda C, O'Rourke C, Eng C, et al. Impact of an embedded genetic counselor on breast cancer treatment. Breast Cancer Res Treat. 2018;169:43\u201346.","journal-title":"Breast Cancer Res Treat"},{"key":"202_CR18","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1245\/s10434-020-09160-8","volume":"28","author":"KA Metcalfe","year":"2021","unstructured":"Metcalfe KA, Eisen A, Poll A, Candib A, McCready D, Cil T, et al. Rapid genetic testing for BRCA1 and BRCA2 mutations at the time of breast cancer diagnosis: an observational study. Ann Surg Oncol. 2021;28:2219\u201326.","journal-title":"Ann Surg Oncol"},{"key":"202_CR19","doi-asserted-by":"publisher","first-page":"103797","DOI":"10.1016\/j.critrevonc.2022.103797","volume":"178","author":"M Charron","year":"2022","unstructured":"Charron M, Kaiser B, Dauge A, Gallois H, Lapointe J, Dorval M, et al. Integrating hereditary breast and ovarian cancer genetic counselling and testing into mainstream clinical practice: Legal and ethical challenges. Crit Rev Oncol Hematol. 2022;178:103797.","journal-title":"Crit Rev Oncol Hematol"},{"key":"202_CR20","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1159\/000511136","volume":"16","author":"J Dick","year":"2021","unstructured":"Dick J, Aue V, Wesselmann S, Br\u00e9dart A, Dolbeault S, Devilee P, et al. Survey on physicians' knowledge and training needs in genetic counseling in Germany. Breast Care (Basel). 2021;16:389\u201395.","journal-title":"Breast Care (Basel)"},{"key":"202_CR21","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s10689-019-00122-y","volume":"18","author":"N Hallowell","year":"2019","unstructured":"Hallowell N, Wright S, Stirling D, Gourley C, Young O, Porteous M. Moving into the mainstream: healthcare professionals' views of implementing treatment focussed genetic testing in breast cancer care. Fam Cancer. 2019;18:293\u2013301.","journal-title":"Fam Cancer"},{"key":"202_CR22","doi-asserted-by":"publisher","first-page":"690","DOI":"10.12968\/bjon.2016.25.12.690","volume":"25","author":"N Percival","year":"2016","unstructured":"Percival N, George A, Gyertson J, Hamill M, Fernandes A, Davies E, et al. The integration of BRCA testing into oncology clinics. Br J Nurs. 2016;25:690\u20134.","journal-title":"Br J Nurs"},{"key":"202_CR23","doi-asserted-by":"publisher","first-page":"e204","DOI":"10.1200\/OP.20.00399","volume":"17","author":"T Scheinberg","year":"2021","unstructured":"Scheinberg T, Goodwin A, Ip E, Linton A, Mak B, Smith DP, et al. Evaluation of a mainstream model of genetic testing for men with prostate cancer. JCO Oncol Pract. 2021;17:e204\u2013e216.","journal-title":"JCO Oncol Pract"},{"key":"202_CR24","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1056\/NEJM199703203361202","volume":"336","author":"FM Giardiello","year":"1997","unstructured":"Giardiello FM, Brensinger JD, Petersen GM, Luce MC, Hylind LM, Bacon, et al. The use and interpretation of commercial APC gene testing for familial adenomatous polyposis. N Engl J Med. 1997;336:823\u20137.","journal-title":"N Engl J Med"},{"key":"202_CR25","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/s41431-021-00848-3","volume":"29","author":"C Beard","year":"2021","unstructured":"Beard C, Monohan K, Cicciarelli L, James PA. Mainstream genetic testing for breast cancer patients: early experiences from the Parkville Familial Cancer Centre. Eur J Hum Genet. 2021;29:872\u201380.","journal-title":"Eur J Hum Genet"},{"key":"202_CR26","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1007\/s11912-022-01340-x","volume":"24","author":"PV Bhardwaj","year":"2022","unstructured":"Bhardwaj PV, Abdou YG. Germline genetic testing in breast cancer: systemic therapy implications. Curr Oncol Rep. 2022;24:1791\u2013800.","journal-title":"Curr Oncol Rep"},{"key":"202_CR27","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1200\/JCO.2016.71.6480","volume":"35","author":"AW Kurian","year":"2017","unstructured":"Kurian AW, Li Y, Hamilton AS, Ward KC, Hawley ST, Morrow M, et al. Gaps in incorporating germline genetic testing into treatment decision-making for early-stage breast cancer. J Clin Oncol. 2017;35:2232\u20139.","journal-title":"J Clin Oncol"},{"key":"202_CR28","doi-asserted-by":"crossref","unstructured":"Kwong A, Shin VY, Ho CYS, Au CH, Slavin TP, Weitzel JN, et al. Mutation screening of germline TP53 mutations in high-risk Chinese breast cancer patients. BMC Cancer. 2020;20:1053.","DOI":"10.1186\/s12885-020-07476-y"},{"key":"202_CR29","doi-asserted-by":"publisher","first-page":"104350","DOI":"10.1016\/j.ejmg.2021.104350","volume":"64","author":"DH Marmolejo","year":"2021","unstructured":"Marmolejo DH, Wong MYZ, Bajalica-Lagercrantz S, Tischkowitz M, Balma\u00f1a J, Pat\u00f3cs AB, et al. Overview of hereditary breast and ovarian cancer (HBOC) guidelines across Europe. Eur J Med Genet [Internet]. 2021;64:104350.","journal-title":"Eur J Med Genet [Internet]"},{"key":"202_CR30","doi-asserted-by":"publisher","first-page":"e2431427","DOI":"10.1001\/jamanetworkopen.2024.31427","volume":"7","author":"Z Rezoug","year":"2024","unstructured":"Rezoug Z, Totten SP, Szlachtycz D, Atayan A, Mohler K, Albert S, et al. Universal genetic testing for newly diagnosed invasive breast cancer. JAMA Netw Open. 2024;7:e2431427.","journal-title":"JAMA Netw Open"},{"key":"202_CR31","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1245\/s10434-024-16223-7","volume":"32","author":"V Shim","year":"2025","unstructured":"Shim V, Karlea A, Brenman LM, Gul J, Hoodfar E, Chan TD, et al. Mainstream germline genetic testing with expanded eligibility for early breast cancer patients in a large integrated health system. Ann Surg Oncol. 2025;32:75\u201383.","journal-title":"Ann Surg Oncol"},{"key":"202_CR32","unstructured":"Regional Cancercentrum (RCC). Nationella riktlinjer f\u00f6r br\u00f6stcancer {National guidelines for breast cancer care}. 2024, version 5.1."},{"key":"202_CR33","unstructured":"Regional Cancercentrum (RCC). Nationella riktlinjer f\u00f6r br\u00f6stcancer {National guidelines for breast cancer care}. 2023, version 4.3."},{"key":"202_CR34","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/ijc.31841","volume":"144","author":"J Li","year":"2019","unstructured":"Li J, Wen WX, Eklund M, Kvist A, Eriksson M, Christensen H, et al. Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort. Int J Cancer. 2019;144:1195\u2013204.","journal-title":"Int J Cancer"},{"key":"202_CR35","doi-asserted-by":"publisher","first-page":"4071","DOI":"10.1200\/JCO.2016.68.4316","volume":"34","author":"J Balma\u00f1a","year":"2016","unstructured":"Balma\u00f1a J, Digiovanni L, Gaddam P, Walsh MF, Joseph V, Stadler ZK, et al. Conflicting interpretation of genetic variants and cancer risk by commercial laboratories as assessed by the prospective registry of multiplex testing. J Clin Oncol. 2016;34:4071\u20138.","journal-title":"J Clin Oncol"},{"key":"202_CR36","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s10689-019-00153-5","volume":"19","author":"V Petry","year":"2020","unstructured":"Petry V, Bonadio RC, Cagnacci AQC, Senna LAL, Campos RDNG, Cotti GC, et al. P. Radiotherapy-induced malignancies in breast cancer patients with TP53 pathogenic germline variants (Li-Fraumeni syndrome). Fam Cancer. 2020;19:47\u201353.","journal-title":"Fam Cancer"},{"key":"202_CR37","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.ijrobp.2019.07.026","volume":"105","author":"C Bergom","year":"2019","unstructured":"Bergom C, West CM, Higginson DS, Abazeed ME, Arun B, Bentzen SM, et al. The implications of genetic testing on radiation therapy decisions: a guide for radiation oncologists. Int J Radiat Oncol Biol Phys. 2019;105:698\u2013712.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"202_CR38","doi-asserted-by":"crossref","unstructured":"Lee MK, Robson ME. Contralateral breast cancer risk with radiation therapy in BRCA mutation carriers: what do we tell patients? J Natl Cancer Instit. 2023;115:1243\u20135.","DOI":"10.1093\/jnci\/djad129"},{"key":"202_CR39","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1002\/jso.24763","volume":"116","author":"MR Wevers","year":"2017","unstructured":"Wevers MR, Aaronson NK, Bleiker EMA, Hahn DEE, Brouwer T, van Dalen T, et al. Rapid genetic counseling and testing in newly diagnosed breast cancer: patients' and health professionals' attitudes, experiences, and evaluation of effects on treatment decision making. J Surg Oncol. 2017;116:1029\u201339.","journal-title":"J Surg Oncol"},{"key":"202_CR40","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3390\/cancers12010140","volume":"12","author":"V Teoh","year":"2020","unstructured":"Teoh V, Tasoulis MK, Gui G. Contralateral prophylactic mastectomy in women with unilateral breast cancer who are genetic carriers, have a strong family history or are just young at presentation. Cancers (Basel). 2020;12:140.","journal-title":"Cancers (Basel)"},{"key":"202_CR41","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ygyno.2014.05.028","volume":"134","author":"E Lokich","year":"2014","unstructured":"Lokich E, Stuckey A, Raker C, Wilbur JS, Laprise J, Gass J. Preoperative genetic testing affects surgical decision making in breast cancer patients. Gynecol Oncol. 2014;134:326\u201330.","journal-title":"Gynecol Oncol"},{"key":"202_CR42","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1245\/s10434-016-5328-7","volume":"23","author":"A Chiba","year":"2016","unstructured":"Chiba A, Hoskin TL, Hallberg EJ, Cogswell JA, Heins CN, Couch FJ, et al. Impact that timing of genetic mutation diagnosis has on surgical decision making and outcome for BRCA1\/BRCA2 mutation carriers with breast cancer. Ann Surg Oncol. 2016;23:3232\u20138.","journal-title":"Ann Surg Oncol"},{"key":"202_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-018-2957-5","volume":"18","author":"DD Stenehjem","year":"2018","unstructured":"Stenehjem DD, Au T, Sainski AM, Bauer H, Brown K, Lancaster J, et al. Impact of a genetic counseling requirement prior to genetic testing. BMC Health Serv Res. 2018;18:165.","journal-title":"BMC Health Serv Res"},{"key":"202_CR44","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s10689-021-00261-1","volume":"21","author":"B Meiser","year":"2022","unstructured":"Meiser B, Woodward P, Gleeson M, Kentwell M, Fan HM, Antill Y, et al. Pilot study of an online training program to increase genetic literacy and communication skills in oncology healthcare professionals discussing BRCA1\/2 genetic testing with breast and ovarian cancer patients. Fam Cancer. 2022;21:157\u201366.","journal-title":"Fam Cancer"},{"key":"202_CR45","doi-asserted-by":"publisher","first-page":"e2222092","DOI":"10.1001\/jamanetworkopen.2022.22092","volume":"5","author":"R Kukafka","year":"2022","unstructured":"Kukafka R, Pan S, Silverman T, Zhang T, Chung WK, Terry MB, et al. Patient and clinician decision support to increase genetic counseling for hereditary breast and ovarian cancer syndrome in primary care: a cluster randomized clinical trial. JAMA Netw Open. 2022;5:e2222092.","journal-title":"JAMA Netw Open"},{"key":"202_CR46","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s12094-015-1470-0","volume":"18","author":"L Moreno","year":"2016","unstructured":"Moreno L, Linossi C, Esteban I, Gadea N, Carrasco E, Bonache S, et al. Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer therapeutics. Clin Transl Oncol. 2016;18:981\u20137.","journal-title":"Clin Transl Oncol"},{"key":"202_CR47","first-page":"143","volume":"13","author":"AS Sie","year":"2014","unstructured":"Sie AS, van Zelst-Stams WA, Spruijt L, Mensenkamp AR, Ligtenberg MJ, Brunner HG, et al. More breast cancer patients prefer BRCA-mutation testing without prior face-to-face genetic counseling. Fam Cancer. 2014;13:143\u201351.","journal-title":"Fam Cancer"},{"key":"202_CR48","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10689-020-00160-x","volume":"19","author":"EM Grindedal","year":"2020","unstructured":"Grindedal EM, J\u00f8rgensen K, Olsson P, Gravdehaug B, Lur\u00e5s H, Schlichting E, et al. Mainstreamed genetic testing of breast cancer patients in two hospitals in South Eastern Norway. Fam Cancer. 2020;19:133\u201342.","journal-title":"Fam Cancer"},{"key":"202_CR49","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.pec.2017.11.016","volume":"101","author":"C Grimmett","year":"2018","unstructured":"Grimmett C, Pickett K, Shepherd J, Welch K, Recio- Saucedo A, Streit E, et al. Systematic review of the empirical investigation of resources to support decision-making regarding BRCA1 and BRCA2 genetic testing in women with breast cancer. Patient Educ Couns. 2018;101:779\u201388.","journal-title":"Patient Educ Couns"},{"key":"202_CR50","doi-asserted-by":"crossref","unstructured":"Watts KJ, Meiser B, Mitchell G, Kirk J, Saunders C, Peate M, et al. TFGT Collaborative Group. How should we discuss genetic testing with women newly diagnosed with breast cancer? Design and implementation of a randomized controlled trial of two models of delivering education about treatment-focused genetic testing to younger women newly diagnosed with breast cancer. BMC Cancer. 2012;12:320.","DOI":"10.1186\/1471-2407-12-320"}],"container-title":["BJC Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44276-025-00202-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44276-025-00202-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44276-025-00202-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T15:04:16Z","timestamp":1770131056000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44276-025-00202-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["202"],"URL":"https:\/\/doi.org\/10.1038\/s44276-025-00202-w","relation":{},"ISSN":["2731-9377"],"issn-type":[{"value":"2731-9377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"2 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MT is Editor-in-Chief of BJC Reports but did not have a role in the peer review assessment or any decision-making for this paper. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}